
    
      The prognosis of gastric cancer is poor partially due to low R0 resection rate. Neoadjuvant
      chemoradiotherapy was reported to be effective in this setting by several phase II studies.
      The investigators aim to evaluate the efficacy and toxicity of neoadjuvant chemoradiotherapy
      in a prospective phase II study.
    
  